John Groves, DO
Family Medicine · Medford, ORNPI 1801202312
Payments from drug & device makers
Across 171 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$673
- AstraZeneca$304
- Astellas Pharma US Inc$242
- Novo Nordisk$175
- Bayer$167
- Abbott$160
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,93195%
- Education$943%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $673 |
| AstraZeneca | 14 | $304 |
| Astellas Pharma US Inc | 10 | $242 |
| Novo Nordisk | 11 | $175 |
| Bayer | 9 | $167 |
| Abbott | 7 | $160 |
| Pfizer | 7 | $129 |
| Merck | 6 | $121 |
| Lilly USA, LLC | 7 | $116 |
| Axsome Therapeutics, Inc. | 6 | $105 |
| Dexcom, Inc. | 5 | $92 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Gilead | 4 | $67 |
| Esperion Therapeutics, Inc. | 4 | $64 |
| Amgen | 4 | $62 |
| Mannkind Corporation | 1 | $59 |
| Exact Sciences | 3 | $54 |
| GSK | 2 | $51 |
| Kestra Medical Technology Services, Inc. | 1 | $47 |
| Amarin Pharma, Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Novartis | 2 | $25 |
| Smith+Nephew | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,084 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $79,928 |
| OzempicSemaglutide | 64 | $79,368 |
| LinzessLinaclotide | 54 | $50,215 |
| TrulicityDulaglutide | 21 | $40,713 |
| EliquisApixaban | 47 | $40,120 |
| JanuviaSitagliptin Phosphate | 37 | $39,260 |
| FarxigaDapagliflozin Propanediol | 45 | $33,807 |
| JardianceEmpagliflozin | 29 | $32,261 |
| RybelsusSemaglutide | 15 | $20,511 |
| TradjentaLinagliptin | 17 | $19,477 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $16,024 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $15,462 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $15,446 |
| XareltoRivaroxaban | 15 | $13,738 |
| MyrbetriqMirabegron | 18 | $12,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $116 | $120,64188 claims |
| Novo NordiskOzempic, Rybelsus | $175 | $99,87879 claims |
| MerckJanuvia, Janumet, Belsomra | $121 | $64,30772 claims |
| AbbVieLinzess | $673 | $50,21554 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $304 | $49,25258 claims |
| PfizerEliquis, Premarin | $129 | $43,48560 claims |
| Johnson & JohnsonXarelto | $15 | $13,73815 claims |
| Astellas Pharma US IncMyrbetriq | $242 | $12,48118 claims |
| GSKTrelegy Ellipta | $51 | $9,90515 claims |
| NovartisEntresto | $25 | $8,07812 claims |
| Eisai Inc.Dayvigo | $12 | $7,23522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Medford
- Stephen NelsonMedford$101K
- Nathaniel FondellMedford$21K
- Cindy KonecneMedford$10K
- John DelgadoAshland$4.3M
- John MickelsonLincoln City$2.1M
- Subramaniam SeetharamanMilwaukie$1.8M
- Eden MillerBend$1.7M
- Maureen MaysPortland$491K
- Thomas TurkRoseburg$434K
- Anil RajaniHood River$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.